Key Takeaways
- Export collapse drove a 13% revenue drop: Revenue fell to ₹522 crore and PAT halved to ₹11 crore, almost entirely because export volumes shrank 34% on weak global demand and Chinese oversupply.
- Gross margin jumped 300–350 bps despite the top-line hit: The domestic business improved margins through pricing actions and mix, while seeds lifted both gross margin and PBT, partially insulating profitability.
- Domestic volumes are growing but pricing remains under pressure: Domestic crop care grew volumes (herbicides +41%, biologicals +21%) yet revenue still dipped 2% as steep price corrections and aggressive trade schemes persisted.
- The export portfolio is being actively reshaped, not just waited out: Management is flexibilising plants, pruning low-margin products, adding CSM customers, and commercialising Metalaxyl-M, but new customer wins take time.
- What to watch next quarter: Whether the portfolio rationalisation and CSM pipeline additions begin to show in revenue, and whether rabi season pest pressure lifts domestic fungicide/insecticide offtake.
Export Business: The Quarter's Central Problem
- Volume and price both fell: Export revenue dropped 38% YoY, with volumes down 34% and price down 4%, as weak demand hit most key products.
- China's overcapacity is the structural headwind: Chinese agrochemical oversupply, direct market participation, and price undercutting are pressuring Indian exporters, and management sees no near-term resolution.
- Product-level pain is concentrated but spreading: Acephate faces margin challenges from input-cost volatility and high supply; Pendimethalin is now under pressure from high customer inventory and Chinese competition, joining Acephate as a problem child. Metribuzin and Hexaconazole are the relative bright spots.
- The 2025 global outlook is muted: Management stated the forecast for international business "is not very strong," citing low corn, soybean and wheat commodity prices and weakness driven by the Americas.
Dr. Gyanendra Shukla: "But given the global context of the market, I think global market forecast, given the commodity prices of key commodities like corn and soybean, including wheat remain low. The forecast for 2025 I do not think is very strong as far as international business is concerned."
Domestic Crop Care: Volume Resilience, Price Pain
- Volumes grew but revenue did not: Domestic crop care grew volumes in Q3 yet revenue fell 2% due to steep price corrections; on a YTD basis, revenue grew 6% with volume growth.
- Herbicides and biologicals are the growth engines: Herbicide volumes rose 41% and biologicals & specialty solutions grew 21% in the domestic business this quarter. GeoGreen, RalliGold Granule, and bio-stimulants recorded their highest-ever YTD sales.
- Water-soluble fertiliser is scaling fast: The category grew 80% in the last nine months, signalling successful new-product adoption.
- Q3 was weakened by a poor herbicide season: Q3 is typically a strong herbicide quarter for wheat, sugarcane and rice, but an abrupt monsoon cessation in September and a weak chilli season (low chilli prices) hurt offtake.
- Trade inventory and pricing pressure are widespread: Post-monsoon cyclones Dana and Fengal created trade inventory pressure, forcing aggressive schemes. Management noted "everybody's sitting on the inventory" and pricing pressure continues.
- Innovation is happening but scaling is the gap: The innovation turnover index is in the high teens, in line with ambition, but management acknowledged a gap in the ability to launch and scale new products and is revamping its go-to-market approach.
Margin & Portfolio Actions
- Gross margin rose sharply despite the revenue decline: A ~300–350 bps increase was driven by domestic pricing actions, right inventory levels, a favourable mix (international underperformed), and seeds improving both gross margin and PBT.
- Portfolio rationalisation is complete, impact ahead: Management has finished pruning low-margin products and is careful not to build inventory of them; the revenue impact will be immaterial, but sales-team effort and supply-chain complexity should reduce.
- SKU complexity is being tackled: The long tail of SKUs is under review not because of low profitability but because serving many SKUs consumes disproportionate sales effort and supply-chain bandwidth.
- Capex is being moderated: Management is moderating capex in line with demand and focusing on improving utilisation and ROI on already-invested capital.
- Solar and process investments continue: The Board approved solar panel installation to cut electricity costs and carbon footprint, while the CSTR process for Pendimethalin is going live this quarter.
Seeds: Small Quarter, Bigger Story
- Q3 is seasonally small for seeds: Revenue was ₹30 crore vs ₹32 crore last year, mainly due to lower hybrid mustard seed sales.
- YTD performance is strong: Revenue grew 1% but profit before tax jumped 55%, despite product availability constraints limiting scale-up of new launches like Diggaz. Cotton became the biggest crop with sales exceeding ₹100 crore.
- Seed production remains a constraint for the second year: Production is "slightly better than last year" but area remains tight because farmers weigh commercial crop returns against seed crop economics. Input costs have risen steeply while volumes are under pressure.
Strategic Shifts: CSM, Digital & the Domestic Bet
- All B2B businesses are now unified: The move brings all B2B operations under one roof to drive strategic partnerships and alliances for both domestic and international markets.
- CSM is the long-term export answer: Management is expanding the customer base, working on new chemistries, and has set up labs; it is working with 10 new customers and adding more for Metribuzin, Pendimethalin and Hexaconazole. Metalaxyl-M has reached the commercial stage.
- New customer wins take time: Sampling, testing and vendor approval cycles mean CSM contributions will build over years, not quarters.
- Digital farmer connect is being piloted: A digital-based influencer approach to improve farmer engagement is being piloted, and WhatsApp for Business has gone live. Management is making "a lot of investment on digital connectivity with the farmer."
- Domestic is the priority: Management reiterated that the primary focus is to drive domestic, where Rallis has brand equity, and is more optimistic about domestic than international given the global scenario.
Dr. Gyanendra Shukla: "That's why domestic have become very important for us. I think I have been saying probably for last three, four calls, our primary focus is to drive domestic. We have lot of opportunities to fix in, I mean, we have opportunities in CSM, we have opportunities to participate in international business. But given the scenario there I am more optimistic about domestic because that's where we have brand equity."
The Export Portfolio Reset
- The portfolio is not new, and management knows it: The export basket relies on mature molecules (Acephate, Pendimethalin, Metribuzin, Hexaconazole), and management is trying to extract maximum advantage from what it has while slowly switching to a newer portfolio.
- Plant flexibilisation is underway: For Acephate, the company is working on flexibilising the plant and optimising overheads to cope with margin challenges. The multipurpose plant has taken Difenoconazole batches and is now pursuing contract manufacturing opportunities, including one with a global major.
- Metalaxyl-M is the nearest new molecule: Commercialisation is in final stages from the reverse-engineering pipeline, and management is confident of its long-term potential for both domestic and international markets.
- China's direct market participation is a watchpoint: Chinese companies have started participating directly in global markets; management believes this creates diversification opportunities for India as an alternate supplier, but the dynamic is uncertain.
Dr. Gyanendra Shukla: "But we know that we do not have a very, very new portfolio. But within that we are trying to really take maximum advantage of what we have, also trying to slowly switch over to a newer portfolio."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Portfolio rationalisation impact | Impact of pruning low-margin products to be visible | Subsequent quarters |
| EBITDA margin | "We will try to maintain EBITDA margin" | Short term |
| Volume growth and margins | "We will try to improve volume growth and margins in a tough environment" | Undated |
| Capacity utilisation | "Our endeavor would be to improve capacity utilization and take steps to improve market share across verticals" | Undated |
| Capex | Moderated in line with demand; focus on utilisation and ROI of already-invested capex | Ongoing |
| CSM contribution | Confident efforts will start contributing meaningfully to top line and bottom line | "In years to come" |
| Digital influencer rollout | Being piloted; expect to roll nationally | "Soon" |
| IRR target | "Certainly more than the Weighted Average Cost of Capital" | Undated |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹522 cr, 13% degrowth YoY |
| Domestic revenue | ₹492 cr, large proportion from domestic crop care |
| International revenue | ₹110 cr |
| PAT | ₹11 cr, versus ₹24 cr in Q3 FY24 |
| YTD PBT | Largely flat on PBT basis despite market challenges |
| Gross margin | Improved 300–350 bps YoY, driven by domestic pricing actions and mix |
| Domestic crop care revenue | Down 2% YoY due to steep price correction; YTD growth of 6% with volume growth |
| Domestic volume growth | 3% YoY |
| Domestic price realization | ~5% decline YoY |
| Export business degrowth | 38% YoY, volume dropping 34% and price dropping 4% |
| Herbicides volume growth (domestic) | 41% YoY |
| Biologicals and specialty solutions volume growth (domestic) | 21% YoY |
| Biologicals and specialty solutions revenue growth | 13% YoY on Q3 basis, 24% on YTD basis |
| Water soluble fertilizer growth | 80% in the last nine months |
| Innovation turnover index | Above 15%, in the high teens |
| Seed business revenue | ₹30 cr, versus ₹32 cr in Q3 FY24 |
| Seed business YTD revenue growth | 1% YoY |
| Seed business YTD PBT growth | 55% YoY |
| Cotton sales | More than ₹100 cr |
| Cash and liquid fund balance | More than ₹200 cr as of 31 Dec 2024 |